ARS Pharmaceuticals Statistics
Share Statistics
ARS Pharmaceuticals has 97.19M shares outstanding. The number of shares has increased by 0.71% in one year.
| Shares Outstanding | 97.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 51.12M |
| Failed to Deliver (FTD) Shares | 19.09K |
| FTD / Avg. Volume | 1.55% |
Short Selling Information
The latest short interest is 12.66M, so 13.02% of the outstanding shares have been sold short.
| Short Interest | 12.66M |
| Short % of Shares Out | 13.02% |
| Short % of Float | 24.76% |
| Short Ratio (days to cover) | 10.98 |
Valuation Ratios
The PE ratio is -9.6 and the forward PE ratio is -21.12.
| PE Ratio | -9.6 |
| Forward PE | -21.12 |
| PS Ratio | 17392.67 |
| Forward PS | 5.1 |
| PB Ratio | 2.26 |
| P/FCF Ratio | -8.78 |
| PEG Ratio | n/a |
Enterprise Valuation
ARS Pharmaceuticals Inc. has an Enterprise Value (EV) of 451.08M.
| EV / Earnings | -8.3 |
| EV / Sales | 15036.1 |
| EV / EBITDA | -6.69 |
| EV / EBIT | -6.68 |
| EV / FCF | -7.59 |
Financial Position
The company has a current ratio of 96.92, with a Debt / Equity ratio of 0.
| Current Ratio | 96.92 |
| Quick Ratio | 96.92 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.24% and return on capital (ROIC) is -29.23%.
| Return on Equity (ROE) | -0.24% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -29.23% |
| Revenue Per Employee | 1.25K |
| Profits Per Employee | -2.27M |
| Employee Count | 24 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 91.25% in the last 52 weeks. The beta is 1, so ARS Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | 91.25% |
| 50-Day Moving Average | 13.12 |
| 200-Day Moving Average | 11.58 |
| Relative Strength Index (RSI) | 43.23 |
| Average Volume (20 Days) | 1.23M |
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 30.00K and earned -54.37M in profits. Earnings per share was -0.57.
| Revenue | 30.00K |
| Gross Profit | -43.00K |
| Operating Income | -67.52M |
| Net Income | -54.37M |
| EBITDA | -67.45M |
| EBIT | -67.52M |
| Earnings Per Share (EPS) | -0.57 |
Balance Sheet
The company has 70.97M in cash and 274.00K in debt, giving a net cash position of 70.70M.
| Cash & Cash Equivalents | 70.97M |
| Total Debt | 274.00K |
| Net Cash | 70.70M |
| Retained Earnings | -131.30M |
| Total Assets | 217.60M |
| Working Capital | 192.17M |
Cash Flow
In the last 12 months, operating cash flow was -59.27M and capital expenditures -175.00K, giving a free cash flow of -59.44M.
| Operating Cash Flow | -59.27M |
| Capital Expenditures | -175.00K |
| Free Cash Flow | -59.44M |
| FCF Per Share | -0.62 |
Margins
Gross margin is -143.33%, with operating and profit margins of -225.07K% and -181.22K%.
| Gross Margin | -143.33% |
| Operating Margin | -225.07K% |
| Pretax Margin | -181.22K% |
| Profit Margin | -181.22K% |
| EBITDA Margin | -224.82K% |
| EBIT Margin | -225.07K% |
| FCF Margin | -198.14K% |
Dividends & Yields
SPRY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.02% |
| FCF Yield | -5.38% |
Analyst Forecast
The average price target for SPRY is $28, which is 146.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 146.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 37.91 |
| Piotroski F-Score | 3 |